

Â Â UNITEDSTATES SECURITIESAND EXCHANGE COMMISSIONWashington,D.C. 20549Â FORM6-KÂ REPORTOF
FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16UNDERTHE SECURITIES EXCHANGE ACT OF
1934Â Forthe month of January 2025Â CommissionFile Number 001-40996Â MDXHEALTHSA(Translationof
registrantâ€™s name into English)Â CAPBusiness CenterZoneIndustrielle des Hauts-Sarts4040Herstal, Belgium+324
257 70 21(Addressof principal executive office)Â Indicateby check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.Â Form20-F â˜ Â Â Â Form 40-F â˜ Â Â Â

Â MDXHEALTHSAÂ Â OnJanuary 13, 2025,Â MDxHealth SA (the â€œCompanyâ€) issued a press release, a copy of
which is attached hereto as Exhibit99.1.Â Theinformation in the attached Exhibit 99.1 is being furnished and shall not
be deemed â€œfiledâ€ for the purposes of SectionÂ 18of the Securities Exchange Act of 1934, as amended (the
â€œExchange Actâ€), or otherwise subject to the liabilities of thatSection, nor shall it be deemed incorporated by
reference in any filing made by the Company under the Securities Act of 1933, as amended,or the Exchange Act, except
as otherwise set forth herein or as shall be expressly set forth by specific reference in such a filing.Â Exhibit No. Â
Description of Exhibit 99.1 Â Press Release, dated January 13, 2025 Â 1 Â SIGNATURESÂ Pursuantto the
requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its
behalf bythe undersigned, thereunto duly authorized.Â Â MDXHEALTH SA Â Â Â Date: January 13, 2025 By: /s/
Michael McGarrity Â Â Name:Â Michael McGarrity Â Â Title: Chief Executive Officer Â Â 2Â Â

Exhibit99.1Â Â MDxHealthReports Preliminary Fourth Quarter and Full Year 2024 Revenues andIssues 2025 Revenue
Guidance Â IRVINE,CA â€“ January 13, 2025 (GlobeNewswire) â€“ MDxHealth SA (NASDAQ: MDXH) (the
â€œCompanyâ€or â€œmdxhealthâ€), a leading precision diagnostics company, today reported preliminary fourth
quarter and full year 2024revenues and issued 2025 revenue guidance.Â TheCompany expects to report fourth quarter
and full year 2024 revenues of approximately \$24.7 and \$90.0 million, respectively, representingyear-over-year growth
of 28% for both periods. During the fourth quarter, the Company billed 11,789 tissue-based units and 12,036 liquid-
basedunits, representing growth of 50% and 10%, respectively. For the full year, the Company billed 41,586 tissue-
based units and 45,700 liquid-basedunits, representing growth of 31% and 28%, respectively. Cash balance at year-end
was \$46.8 million.Â TheCompany is also issuing 2025 revenue guidance of \$108-110 million, which represents year-
over-year growth of 20-22%, and confirms viewof adjusted EBITDA profitability in the first half of this year.Â MichaelK.
McGarrity, CEO of mdxhealth, commented: â€œWe are pleased to report continued execution on our growth strategy,
with year-over-yearrevenue growth of approximately 28%. We are confident that the strength of our sales channel
coupled with our expanded menu offeringto our urology customer base will continue to drive sustainable growth. Based
on our operating discipline, commercial execution, andthe underlying growth of our end markets, we anticipate 2025
revenue of \$108-110 million, which would represent year-over-year revenuegrowth of approximately 20-
22%.â€Â AboutmdxhealthÂ Mdxhealthis a commercial-stage precision diagnostics company that provides actionable
molecular information to personalize patient diagnosis andtreatment. The Companyâ€™s tests are based on proprietary
genomic, epigenetic (methylation) and other molecular technologies andassist physicians with the diagnosis and
prognosis of urologic cancers and other urologic diseases. The Companyâ€™s U.S. headquartersand laboratory
operations are in Irvine, California, with additional laboratory operations in Plano, Texas. European headquarters arein
Herstal, Belgium. For more information, visit mdxhealth.com and follow us on social media at: twitter.com/mdxhealth,
facebook.com/mdxhealthand linkedin.com/company/mdxhealth.Â 2025Reporting CalendarÂ –February 26, 2025: 2024
FY resultsÂ –May 14, 2025: Q1-2025 financial results and business updateÂ –May 29, 2025: Annual general
shareholdersâ€™ meetingÂ –August 14, 2025: Q2-2025 financial results and business updateÂ –November 12,
2025: Q3-2025 financial results and business updateÂ Financialinformation and auditor reviewÂ Thepreliminary
unaudited financial data for the year ended December 31, 2024 set forth above is derived from preliminary internal
financialreports. The Company has not yet finalized its complete results of operations for the year ended December 31,
2024. The Company and itsauditors may identify items that would require the Company to make adjustments, some of
which could be material, to the preliminary unauditedfinancial data set forth above.Â Formore information:
info@mdxhealth.comÂ LifeSciAdvisors (IR & PR)US:+1 949 271 9223ir@mdxhealth.comÂ Â Thispress release
contains forward-looking statements and estimates with respect to the anticipated future performance of MDxHealth
and themarket in which it operates, all of which involve certain risks and uncertainties. These statements are often, but
are not always, madethrough the use of words or phrases such as â€œpotential,â€ â€œexpect,â€ â€œwill,â€
â€œgoal,â€ â€œnext,â€ â€œpotential,â€ â€œaim,â€ â€œexplore,â€ â€œforward,â€ â€œfuture,â€ and â€œbelievesâ€as
well as similar expressions. Forward-looking statements contained in this release include, but are not limited to,
statements regardingexpected future operating results; our strategies, positioning, resources, capabilities and
expectations for future events or performance;and the anticipated benefits of our acquisitions, including estimated
synergies and other financial impacts. Such statements and estimatesare based on assumptions and assessments of
known and unknown risks, uncertainties and other factors, which were deemed reasonable butmay not prove to be
correct. Actual events are difficult to predict, may depend upon factors that are beyond the companyâ€™s control, and
may turn out to be materially different. Examples of forward-looking statements include, among others, statements we
make regardingexpected future operating results, product development efforts, our strategies, positioning, resources,
capabilities and expectationsfor future events or performance. Important factors that could cause actual results,
conditions and events to differ materially fromthose indicated in the forward-looking statements include, among others,
the following: our ability to successfully and profitably marketour products; the acceptance of our products and services
by healthcare providers; our ability to achieve and maintain adequate levelsof coverage or reimbursement for our
current and future solutions we commercialize or may seek to commercialize; the willingness of healthinsurance
companies and other payers to cover our products and services and adequately reimburse us for such products and
services; ourability to obtain and maintain regulatory approvals and comply with applicable regulations; timing,
progress and results of our researchand development programs; the period over which we estimate our existing cash
will be sufficient to fund our future operating expensesand capital expenditure requirements; our ability to remain in
compliance with financial covenants made to and make scheduled paymentsto our creditors; the possibility that the
anticipated benefits from our business acquisitions like our acquisition of the Oncotype DX®GPS prostate cancer
business will not be realized in full or at all or may take longer to realize than expected; and the amount and natureof
competition for our products and services. Other important risks and uncertainties are described in the Risk Factors
sections of ourmost recent Annual Report on Form 20-F and in our other reports filed with the Securities and Exchange
Commission. MDxHealth expresslydisclaims any obligation to update any such forward-looking statements in this
release to reflect any change in its expectations withregard thereto or any change in events, conditions or

circumstances on which any such statement is based unless required by law or regulation. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of MDxHealth in any jurisdiction. No securities of MDxHealth may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. securities laws. Non-IFRS Measures. The Company's reference to adjusted EBITDA is a forward-looking statement about the Company's future financial performance, and is a non-IFRS measure that excludes a number of expense items that are included in net loss, including adjustments for items like stock-based compensation, acquisition and integration costs, impairment of long-lived assets, fair-value adjustment, loan extinguishment costs, as well as other non-operating, non-recurring expenses that are difficult to predict for future periods because the nature of the adjustments pertain to events that have not yet occurred. As a result, positive adjusted EBITDA may be achieved while a significant net loss persists. Non-IFRS financial information has limitations as an analytical tool and should not be considered in isolation or as a substitute for financial information presented in accordance with IFRS, and such information is referenced for supplemental information purposes only. Management does not forecast many of the excluded items for internal use, as these are difficult to predict for future periods because the nature of the adjustments pertain to events that have not yet occurred. Information reconciling forward-looking non-IFRS measures to IFRS measures is therefore not available without unreasonable effort, and is not provided. The occurrence, timing, and amount of any of the items excluded from IFRS to calculate non-IFRS measures could significantly impact the Company's IFRS results. NOTE: The mdxhealth logo, mdxhealth, Confirm mdx, Select mdx, Resolve mdx, Genomic Prostate Score, GPS and Monitor mdx are trademarks or registered trademarks of MDxHealth SA. The GPS test was formerly known as and is frequently referenced in guidelines, coverage policies, reimbursement decisions, manuscripts and other literature as Oncotype DX Prostate, Oncotype DX GPS, Oncotype DX Genomic Prostate Score, and Oncotype Dx Prostate Cancer Assay, among others. The Oncotype DX trademark, and all other trademarks and service marks, are the property of their respective owners.Â Â Â Â